{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:39Z","timestamp":1793404359121,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 \u00b1 24.1 vs 79.9 \u00b1 28.4 points, p&amp;lt;0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p&amp;lt;0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 \u00b1 653.5 vs 577.4 \u00b1 322.1 pg\/mL, p&amp;lt;0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.851035","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T04:45:07Z","timestamp":1656045907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice"],"prefix":"10.3389","volume":"13","author":[{"given":"Luis M.","family":"P\u00e9rez-Belmonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz-C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda D.","family":"Garc\u00eda de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Avil\u00e9s-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Cobos-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"P\u00e9rez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"L\u00f3pez-Sampalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Rosa","family":"Bernal-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Jansen-Chaparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 P.","family":"Miramontes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"G\u00f3mez-Huelgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/pds.1741","article-title":"Incidence Rates of Heart Failure, Stroke, and Acute Myocardial Infarction Among Type 2 Diabetic Patients Using Insulin Glargine and Other Insulin","volume":"18","author":"Juhaeri","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.04.005","article-title":"National Trends in Diabetes Mellitus Hospitalisation in Spain 1997\u20132010: Analysis of Over 5","volume":"60","author":"Lara-Rojas","year":"2019","journal-title":"4 Millions Admissions Eur J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2017.04.028","article-title":"National Trends in Heart Failure Hospitalization Rates in Patients With Diabetes Mellitus: 1997-2010","volume":"71","author":"P\u00e9rez-Belmonte","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Position Statement From the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-er07","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic Glycemic Management of Type 2 Diabetes in Adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients With Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes With Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, Mortality, and Kidney Outcomes With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/eurjhf\/hft128","article-title":"The Chronic Kidney Disease Epidemiology Collaboration Equation Outperforms the Modification of Diet in Renal Disease Equation for Estimating Glomerular Filtration Rate in Chronic Systolic Heart Failure","volume":"16","author":"Valente","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2010.10.003","article-title":"Validation of the Spanish Version of the Kansas City Cardiomyopathy Questionnaire","volume":"64","author":"Com\u00edn-Colet","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes With Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients With Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2021.04.005","article-title":"Heart Failure Outcomes and Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review of Observational Studies","volume":"15","author":"Alkhezi","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cardfail.2014.10.012","article-title":"Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes","volume":"21","author":"Velez","year":"2015","journal-title":"J Card Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12933-018-0778-9","article-title":"Cardiac Resynchronization Therapy With a Defibrillator (CRTd) in Failing Heart Patients With Type 2 Diabetes Mellitus and Treated by Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RA) Therapy vs. Conventional Hypoglycemic Drugs: Arrhythmic Burden, Hospitalizations for Heart Failure, and CRTd Responders Rate","volume":"17","author":"Sardu","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the Effects of Sodium-Glucose Co-Transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.10.008","article-title":"Effects of SGLT-2 Inhibitors on Health-Related Quality of Life and Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"345","author":"He","year":"2021","journal-title":"Int J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14135","article-title":"The Impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients With Reduced Ejection Fraction With and Without Type 2 Diabetes","volume":"22","author":"Nielsen","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 Receptor Agonists and Kidney Protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(17)30069-1","article-title":"The Potential and Pitfalls of GLP-1 Receptor Agonists for Renal Protection in Type 2 Diabetes","volume":"43","author":"Thomas","year":"2017","journal-title":"Diabetes Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0643-2","article-title":"Sitagliptin Improved Glucose Assimilation in Detriment of Fatty-Acid Utilization in Experimental Type-II Diabetes: Role of GLP-1 Isoforms in Glut4 Receptor Trafficking","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy124","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Disease: From LEADER to EXSCEL","volume":"114","author":"Torekov","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.03.314","article-title":"Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease","volume":"77","author":"Akawi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.133","article-title":"Treatment With Liraglutide may Improve Markers of CVD Reflected by Reduced Levels of Apob","volume":"3","author":"Engelbrechtsen","year":"2017","journal-title":"Obes Sci Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-019-0937-7","article-title":"Greater Glucagon-Like Peptide-1 Responses to Oral Glucose are Associated With Lower Central and Peripheral Blood Pressures","volume":"18","author":"Lundgren","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13652","article-title":"Heart Failure in the Patient With Diabetes: Epidemiology, Aetiology, Prognosis, Therapy and the Effect of Glucose-Lowering Medications","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00812-7","article-title":"Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-Like Peptide-1 Receptor Agonists","volume":"42","author":"Christensen","year":"2019","journal-title":"Drug Saf"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022622","article-title":"An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment","volume":"135","author":"Makam","year":"2017","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092013","article-title":"De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients With Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study","volume":"10","author":"P\u00e9rez-Belmonte","year":"2021","journal-title":"J Clin Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.851035\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T04:45:09Z","timestamp":1656045909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.851035\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":48,"alternative-id":["10.3389\/fendo.2022.851035"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.851035","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"article-number":"851035"}}